This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Neuroendocrine tumors	Histone deacetylase 10 (HDAC10)	Computational and cell culture studies suggest HDAC10 inhibitors could enhance chemotherapy in treating neuroblastoma. In a database of patients with advanced-stage neuroblastoma, high <i>HDAC10</i> expression correlated with poor overall survival. In neuroblastoma cells, <i>HDAC10</i> -targeting small hairpin RNA increased doxorubicin-mediated cell death compared with control shRNA. Next steps include targeting HDAC10 in animal tumor models.	Patented; available for licensing	Oehme, I. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online June 25, 2013; doi:10.1073/pnas.1300113110 Contact: Ina Oehme, German Cancer Research Center, Heidelberg, Germany e-mail: i.oehme@dkfz.de
<i>SciBX</i> 6(29); doi:10.1038/scibx.2013.756 Published online Aug. 1, 2013				